Johnson and Johnson presents new IMAAVYÂ (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained dise

Super League Enterprise, Inc. (SLE) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company has failed to achieve positive free cash flow in any of the last ten quarters and continues to report deep net losses, including a -$4.1M net income in 2026Q1.
Super League Enterprise, Inc. (SLE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Super League Enterprise, Inc. (SLE) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $1.77vs $1.92+7.8% | $3Mvs $3M+7.2% |
| Q2 2026 | Mar 27, 2026 | $9.44vs $3.12-202.6% | $3Mvs $4M-13.7% |
| Q4 2025 | Nov 13, 2025 | $27.61vs $33.97+18.7% | $2Mvs $4M-34.7% |
| Q3 2025 | Aug 14, 2025 | $4.52vs $6.80+33.5% | $3Mvs $3M+15.4% |
Recent stock market news and headlines for Super League Enterprise, Inc. (SLE)
Johnson and Johnson presents new IMAAVYÂ (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained dise

Key metrics vs top competitors for Super League Enterprise, Inc. (SLE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.07 | $214.75K | -0.01 | -29.91% | -182.66% | -232.95% | — | |
| $0.40 | $8.72M | -1.33 | -3.07% | -17.49% | -40.41% | — | |
| $0.35 | $2.35M | -0.04 | -12.12% | -366.24% | -207.29% | — | |
| $47.55 | $34.04B | -30.88 | 35.77% | -20.69% | -289.59% | — | |
| $28.23 | $12.32B | -29.41 | 2.01% | -34.95% | -19.75% | — | |
| $238.53 | $44.29B | -147.24 | 18.16% | -4.48% | -8.57% | — |
Super League Enterprise, Inc. (SLE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Super League Enterprise, Inc. (SLE) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 27, 2026·SEC
May 19, 2026·SEC
May 6, 2026·SEC
Get notified when SLE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Super League Enterprise, Inc. (SLE) stock FAQ — growth, dividends, profitability & financials explained
Super League Enterprise, Inc. (SLE) reported $11.6M in revenue for fiscal year 2025. This represents a 4208% increase from $0.3M in 2016.
Super League Enterprise, Inc. (SLE) saw revenue decline by 29.9% over the past year.
Super League Enterprise, Inc. (SLE) reported a net loss of $20.5M for fiscal year 2025.
Super League Enterprise, Inc. (SLE) has a return on equity (ROE) of -232.9%. Negative ROE indicates the company is unprofitable.
Super League Enterprise, Inc. (SLE) had negative free cash flow of $8.5M in fiscal year 2025, likely due to heavy capital investments.